<DOC>
	<DOCNO>NCT00453388</DOCNO>
	<brief_summary>This phase II trial study well total-body irradiation ( TBI ) work give together fludarabine phosphate cyclophosphamide follow donor bone marrow transplant , mycophenolate mofetil , cyclosporine treat patient Fanconi anemia ( FA ) . Giving low dos chemotherapy , fludarabine phosphate cyclophosphamide , TBI donor bone marrow transplant help stop growth abnormal cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving mycophenolate mofetil cyclosporine transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Phosphate , Cyclophosphamide , Total-Body Irradiation Followed Donor Bone Marrow Transplant , Mycophenolate Mofetil , Cyclosporine Treating Patients With Fanconi Anemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Identify dose total-body irradiation ( TBI ) lead sufficient probability donor engraftment ( &gt; 5 % donor cluster differentiation [ CD ] 3 chimerism ) day +200 . II . Evaluate probability severe acute graft-versus-host disease . SECONDARY OBJECTIVES : I . Evaluate probability overall survival , regimen-related toxicity ( RRT ) , recurrent hematopoietic malignancy patient prior underlying history . II . Examine degree mixed chimerism provide amelioration symptom ( i.e. , infection due neutropenia , hemorrhage due thrombocytopenia ) associate bone marrow failure . III . Determine FA complementation group % initial mosaicism predict engraftment RRT outcomes . OUTLINE : Patients assign 1 4 treatment arm . NOTE : Patients longer receive pre-transplant cyclophosphamide February 2009 . After completion study treatment , patient follow 6 month annually thereafter .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Any patient FA bone marrow ( BM ) failure involve 2 follow 3 lineage : granulocyte count &lt; 0.5 x 10^9/L , platelet count &lt; 20 x 10^9/L , hemoglobin &lt; 8 g/dL Any patient FA require red blood cell platelet transfusion marrow failure Any patient FA lifethreatening BM failure involve single hematopoietic lineage Any patient FA preexist cytogenetic abnormality include hematopoietic malignancy ( acute myeloid leukemia [ AML ] myelodysplastic syndrome [ MDS ] ) morphological remission ( define absence circulate blast bone marrow blast &lt; 5 % assessed morphology ) ; Note hematopoietic recovery require remission status Patients must negative cytotoxic cross match donor DONOR : Related , human leukocyte antigen ( HLA ) haploidentical donor must identical one HLA haplotype mismatch number HLAA , B , C , DRB1 DQB1 locus unshared haplotype DONOR : Unrelated , HLAmatched donor must match HLAA , B , C , DRB1 DQB1 deoxyribonucleic acid ( DNA ) type high resolution routinely available time donor selection ; single allele mismatch HLAA , B , C allow OR single DQB1 mismatch allow DONOR : Bone marrow allow hematopoietic stem cell source DONOR : Haploidentical donor selection base standard institutional criterion , otherwise specific prioritization make amongst suitable available donor Patients available HLAmatched relate donor Significant organ dysfunction would prevent compliance conditioning , graftversushost disease ( GVHD ) prophylaxis , would severely limit probability survival , liver disease/failure ( active hepatitis , moderate severe portal fibrosis/cirrhosis confirm biopsy uncorrectable hepatic synthetic dysfunction ) , lung disease , cardiac disease ( ejection fraction &lt; 35 % , unable obtain ejection fraction , shorten fraction &lt; 26 % ; shorten &lt; 26 % cardiology consult require principal investigator [ PI ] final approval eligibility ) Human immunodeficiency virus ( HIV ) seropositive patient Fertile female unwilling use contraceptive technique twelve month follow treatment , well females pregnant actively breast feed Fertile male unwilling use contraceptive technique twelve month follow treatment AML/MDS morphological relapse , define circulate blast bone marrow blast &gt; = 5 % assessed morphology Active infectious disease concern Karnofsky performance score &lt; 50 Lansky performance score &lt; 40 DONOR : Donors find Fanconi anemia base chromosomal breakage analysis DONOR : Donors expect meet minimum target dose marrow cell ( 1 x 10^8 nucleated cells/kg recipient ideal body weight [ IBW ] ) unwilling bone marrow donor DONOR : HIVpositive donor DONOR : Donors crossmatch positive recipient DONOR : Recipient homozygous mismatch locus ; recipient homozygous HLAA , B , C donor mismatch locus , donor avoid ; exception must discuss PI</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>